In such cases, seroprevalence surveys of SARS-CoV-2 antibodies are important for refining estimates of infection and transmission [12]

In such cases, seroprevalence surveys of SARS-CoV-2 antibodies are important for refining estimates of infection and transmission [12]. == Conclusion == SARS-CoV-2 infection imposes a high burden on the community as detected by high seroprevalence rates. == Introduction == The new coronavirus, officially named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), infected around 155 million people worldwide by the beginning of May 2021, with more than 3 million related deaths [1], and the numbers are steeply increasing every day. In Egypt, the first peak of reported PROTAC ERRα Degrader-2 cases was recorded by June 2020, with about 65,000 infected cases and 2,789 deaths. Reported cases were stable over the summer season, PROTAC ERRα Degrader-2 with around 6,000 cases per month. The infected cases began to surge by November 2020 and reached around 231,803 by the beginning of May 2021, with 13,591 deaths [2]. Egypt is ranked 68th in the world in terms of COVID-19 infections and 8th in terms of COVID-19 deaths. The capital, Cairo, with its high-density population, took the lead among Egyptian governorates in terms of the number of COVID-19 cases, according to data declared by the Egyptian Ministry of PROTAC ERRα Degrader-2 Health [3]. COVID-19 surveillance in Egypt mainly depends on the reported PCR detection that is usually carried out in symptomatic cases. According to the Ministry of Healths announcement in October 2020, the number HDM2 of daily PCR tests can hardly reach 6, 000 when compared to other Arabic countries such as Saudi Arabia and United Arabic Emirates, during the same period [4]. Studies show that about 30%60% of COVID-19 patients have mild or no symptoms and still can spread the infection [5]. Previous studies have suggested that only a small fraction of asymptomatic persons may eventually develop symptoms [68]. These facts add to the struggle of estimating the magnitude of COVID-19 in a community. Many researchers are attempting to estimate the rates of infection in the community through epidemiological models [9,10] or structural assumptions [11]. With limited testing availability and a high proportion of mild and asymptomatic infections, there is an under-ascertainment of SARS-CoV-2 infections through passive case reporting [68]. In such cases, seroprevalence surveys of SARS-CoV-2 antibodies are important for refining estimates of infection and transmission [12]. Moreover, seroprevalence studies can provide information on risk factors for the disease, such as a patients age, location, or underlying health conditions. Furthermore, they could show significant medical data on immune reactions to the virus and provide an understanding of the immune response following infection of SARS-CoV-2 [13]. In hospital settings, the SARS-CoV-2 infection presents a great challenge, where it is highly infectious during the pre-symptomatic period in patients. The nosocomial transmission of COVID-19 to healthcare workers and other patients can have serious impacts on hospital operation, including the suspension of new admissions and the closing of hospital wards. Preadmission screening by PCR is a policy recommended by different agencies, including the Centers for Disease Control and Prevention (CDC) in the US and the Public Health England guidelines, depending on testing capacity and disease prevalence [14]. By the beginning of May 2020, the Ain Shams University (ASU) hospitals in Cairo adopted a universal screening program for all patients requiring admission to the hospitals. The screening process included PCR testing and total antibody assay prior to admission. With scarce data available on the epidemiology of COVID-19 in Egypt, the aim of the present research was to determine the SARS-CoV-2 PCR positivity rate as well the seroprevalence of SARS-CoV-2 antibodies before the ultimate development of a potential second wave of the epidemic in Cairo, Egypt. The findings derive from the full total results of the PROTAC ERRα Degrader-2 universal screening program for patients in ASU clinics in Cairo. == Topics and strategies == The existing study was completed between May 5 and the finish of Oct 2020. The process from the comprehensive analysis was accepted by Ain Shams School Faculty of Medication Analysis Ethics Committee [FWA00017585], research approval amount (FMASU R/2020). Positive situations had been reported towards the Ministry of Health insurance and Population (MOHP). The rules of treatment and isolation protocol from the MOHP were followed. A written up to date consent in Arabic was extracted from individuals or their guardians regarding minors (Arabic and British translations from the consent type are attached in the supplementary components). == Research setting up == This research took place.

---